Supplemental Table 1. Comparison of the Proportion of Subjects Experiencing Solicited Events by Treatment Group

Symptom	Subjects who received NDV-3A (N=189)	Subjects who received placebo (N=191)	Difference in Proportion (95% CI)	p-value
Any symptom	0.33 (0.27-0.41)	0.28 (0.22-0.35)	0.05 (-0.04 – 0.15)	0.266
Any systemic symptom	0.19 (0.14-0.25)	0.16 (0.11-0.22)	0.03 (-0.04 – 0.11)	0.418
Fever	0.01 (0.00-0.04)	0.01 (0.00-0.03)	0.00 (-0.01 – 0.02)	1.00
Feverishness	0.05 (0.02-0.09)	0.02 (0.00-0.05)	0.03 (-0.00 – 0.07)	0.086
Headache	0.05 (0.03-0.10)	0.07 (0.04-0.11)	-0.02 (-0.06 – 0.03)	0.668
Fatigue	0.04 (0.02-0.08)	0.05 (0.02-0.09)	-0.01 (-0.05 – 0.04)	1.00
Arthralgia	0.05 (0.03-0.10)	0.01 (0.00-0.04)	0.04 (0.01 – 0.08)	0.020
Myalgia	0.04 (0.02-0.08)	0.02 (0.01-0.05)	0.02 (-0.01 – 0.06)	0.257
Nausea	0.01 (0.00-0.04)	0.02 (0.00-0.05)	-0.01 (-0.03 – 0.02)	1.00
Vomiting	0.00 (0.00-002)	0.00 (0.00-0.02)	0.00	NA
Diarrhea	0.01 (0.00-0.04)	0.01 (0.00-0.03)	0.00 (-0.01 – 0.02)	0.622
Chills	0.02 (0.01-0.05)	0.03 (0.01-0.07)	-0.01 (-0.04 – 0.02)	0.751
Sweats	0.01 (0.00-0.03)	0.01 (0.00-0.04)	0.00 (-0.02 – 0.01)	1.00
Any local symptom	0.20 (0.15-0.27)	0.16 (0.11-0.22)	0.04 (-0.04 – 0.12)	0.353
Pain	0.20 (0.14-0.26)	0.16 (0.11-0.22)	0.04 (-0.04 – 0.11)	0.424
Erythema	0.01 (0.00-0.04)	0.00 (0.00-0.02)	0.01 (-0.00 – 0.03)	0.247
Swelling	0.01 (0.00-0.04)	0.00 (0.00-0.02)	0.01 (-0.00 – 0.03)	0.247

Note: The solicited systemic symptom of fever was defined as a documented oral temperature of 100.4–101.1° F (mild), 101.2–102.0°F (moderate), and >102.1–104.0° F (severe). Feverishness was a subjective measure, as reported by the study participant.

Supplemental Figure 1. Maximum Severity of Solicited Systemic Symptoms Per Subject by Treatment Group



Supplemental Figure 2. Maximum Severity of Solicited Local Symptoms Per Subject by Treatment Group



Supplemental Table 2a. Geometric Mean Titer (GMT) of *S. aureus* Als3-IgG in Saliva by Time Point, Treatment Group, and Baseline Nasal Colonization Status

Time Point	Statistic	Baseline *S. aureus* Nasal Colonization Negative Subjects		Baseline *S. aureus* Nasal Colonization Positive Subjects		All Subjects	
		NDV-3A (N=20)	Placebo (N=10)	NDV-3A (N=7)	Placebo (N=4)	NDV-3A (N=27)	Placebo (N=14)
Visit 1: Pre-Vaccination							
	N	20	10	7	4	27	14
	GMT	7	7	6	21	7	9
	95% CI	5 - 10	5 - 10	4 - 8	1 - 375	5 - 9	5 - 18
Visit 3: Day 14							
	N	20	10	7	4	27	14
	GMT	53	8	63	12	55	9
	95% CI	23 - 120	5 - 14	13 - 302	2 - 95	28 - 108	5 - 15

Supplemental Table 2b. Geometric Mean Titer (GMT) of *S. aureus* Als3-IgA1 in Saliva by Time Point, Treatment Group, and Baseline Nasal Colonization Status

Time Point	Statistic	Baseline *S. aureus* Nasal Colonization Negative Subjects		Baseline *S. aureus* Nasal Colonization Positive Subjects		All Subjects	
		NDV-3A (N-20)	Placebo (N=10)	NDV-3A (N=7)	Placebo (N=4)	NDV-3A (N=27)	Placebo (N=14)
Visit 1: Pre-vaccination							
	N	20	10	7	3	27	13
	GMT	106	31	106	742	106	65
	95% CI	33-340	6-173	8-1475	0–>1,000,000	39-288	12-352
Visit 3: Day 14							
	N	20	10	7	4	27	14
	GMT	268	123	2833	2481	494	291
	95% CI	73-987	14-1052	642-12,505	52-118,477	169-1446	49-1733

Supplemental Table 3. Number and Proportion of Study Participants Who Were Colonized at the Pre-Vaccination Visit by Study Group and by Training Company

Site of Colonization	Study Group	Total	Distribution by Training Company			
			Cohort A (N=82)	Cohort B (N=120)	Cohort C (C=89)	Cohort D (N=89)
Nasal	NDV-3A, n=189	63 (33.33)	16 / 41 (39.02)	20 / 60 (33.33)	12 / 44 (27.27)	15 / 44 (34.09)
	Placebo, n=191	61 (31.94)	8 / 41 (19.51)	20 / 60 (33.33)	18 / 45 (40)	15 / 45 (33.33)

Oral	NDV-3A, n=189	93 (49.21)	14 / 41 (34.15)	36 / 60 (60)	21 / 44 (47.73)	22 / 44 (50)
	Placebo, n=191	91 (47.64)	21 / 41 (51.22)	28 / 60 (46.67)	25 / 45 (55.56)	17 / 45 (37.78)
Nasal/Oral	NDV-3A, n=189	113 (59.79)	22 / 41 (53.66)	40 / 60 (66.67)	26 / 44 (59.09)	25 / 44 (56.82)
	Placebo, n=191	112 (58.64)	24 / 41 (58.54)	32 / 60 (53.33)	31 / 45 (68.89)	25 / 45 (55.56)

Note: the nasal/oral endpoint was defined as a subject who had a positive *S. aureus* culture on either the nasal or the oral swab for a given timepoint

Supplemental Figure 3. Proportion and 95% Clopper Pearson Confidence Interval of *S. aureus* Positive Participants by Treatment Group and Study Visit Number -- Baseline *S. aureus* Nasal (a), Oral (b), and Nasal/Oral (c) Colonization Positive Subjects. The number of participants included in each analysis timepoint is included in the table.

(a) Nasal



	Study Visit Number				
Study Group	**1**	**3**	**4**	**5**	**6**

NDV-3A	62	62	43	33	18
Placebo	62	61	41	31	18

(b) Oral



	Study Visit Number

Study Group	1	3	4	5	6
NDV-3A	91	91	21	4	1
Placebo	89	89	23	6	3

(c) Nasal / Oral



	Study Visit Number

Study Group	1	3	4	5	6
NDV-3A	111	111	60	42	25
Placebo	110	110	63	44	25